Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D
June 24, 2023 05:30 ET
|
Vir Biotechnology, Inc.
– Data from two ongoing clinical trials in people living with chronic hepatitis B infection suggest the combination of an antiviral with an immunomodulator can achieve rapid and deep declines in...
Inventiva announces five scientific presentations at the EASL International Liver Congress™ 2023
June 07, 2023 16:00 ET
|
INVENTIVA
Five poster presentations showing : the correlation between the improvement of hepatic steatosis and a robust increase in adiponectin levels, improvement in lipid profile and glycemic control in...
Inventiva annonce cinq présentations scientifiques lors de l’EASL International Liver Congress™ 2023
June 07, 2023 16:00 ET
|
INVENTIVA
Cinq présentations par poster démontrant : La corrélation entre l'amélioration de la stéatose hépatique et une forte augmentation du taux d'adiponectine, l’amélioration du profil lipidique et du...
Sagimet Biosciences to Present Interim Data from Phase 2b Trial of Denifanstat in NASH at EASL Congress 2023
June 07, 2023 09:00 ET
|
Sagimet Biosciences Inc.
SAN MATEO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways,...
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B and D Data Accepted for Presentation at EASL™ Congress 2023
June 07, 2023 02:13 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, June 07, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that five abstracts highlighting new data from the Company’s broad hepatitis portfolio...
Inventiva to host a webcast with Key Opinion Leaders following the EASL International Liver Congress™ 2022
June 16, 2022 16:00 ET
|
INVENTIVA
Update on Inventiva’s NATiV3 Phase III clinical trial evaluating lanifibranor in patients with NASH and fibrosis (stage F2/F3) non-cirrhotic by Prof. Sven FrancqueUpdate on the current NASH landscape...
Inventiva organise un webcast avec des leaders d’opinion à l’occasion de l’EASL International Liver Congress™ 2022
June 16, 2022 16:00 ET
|
INVENTIVA
Point sur l’étude clinique de Phase III NATiV3 d'Inventiva évaluant lanifibranor chez les patients atteints de NASH et de fibrose (stade F2/F3) non cirrhotique par le Prof. Sven FrancquePoint sur le...
Inventiva announces three scientific presentations at the EASL International Liver Congress™ 2022
June 09, 2022 16:00 ET
|
INVENTIVA
Three poster presentations showing the beneficial effects of lanifibranor on markers of cardiometabolic health in patients with non-cirrhotic NASH fibrosis independent of weight gain observed.the...
Inventiva annonce la présentation de trois abstracts scientifiques lors de l’EASL International Liver Congress™ 2022
June 09, 2022 16:00 ET
|
INVENTIVA
Trois présentations par poster démontrant : les effets bénéfiques de lanifibranor sur les marqueurs de la santé cardiométabolique chez les patients atteints de NASH avec fibrose non cirrhotique,...
Enochian BioSciences Announces Scientific Presentation of Elimination of HBV in Mice with No Evident Toxicity
June 30, 2021 07:00 ET
|
Enochian BioSciences, Inc.
LOS ANGELES, June 30, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today...